Market Herald logo

Subscribe

Be the first with the news that moves the market
  • WPD Pharmaceuticals (WBIO) to present at the 10th Congress of the Polish Society of Pediatric Oncology and Hematology
  • WPD will present the key assumptions of the WPD-201P Clinical Trial Protocol, which is planned to start in Q2 2021, as a part of the research project
  • Berubicin is a second-generation anthracycline candidate for the treatment of a number of Central Nervous System Cancers, including Glioblastoma Multiforme (GBM) and Malignant Gliomas
  • WPD also announces it has engaged Strikepoint Media LLC., to provide digital marketing and brand awareness support
  • WPD is a biotechnology research and development company with a focus on oncology and virology
  • WPD Pharmaceuticals Inc. (WBIO) is down 1.72 per cent and is trading at C$0.28 at 12:24 pm ET

WPD Pharmaceuticals Inc. (WBIO) will attend the 10th Annual Congress of the Polish Society of Pediatric Oncology and Hematology.

The event will be held on May 6-8, 2021.

During the Congress, WPD will present the key assumptions of the WPD-201P Clinical Trial Protocol, which is planned to start in Q2 2021, as a part of the research project.

The project is titled, “New approach to glioblastoma treatment addressing the critical unmet medical need”, granted by National Research and Development Center and co-financed by the European Union, under the Smart Growth Operational Program 2014-2020.

Berubicin is a second-generation anthracycline candidate for the treatment of a number of Central Nervous System Cancers, including Glioblastoma Multiforme (GBM) and Malignant Gliomas.

Anthracyclines are designed to utilize natural processes to induce deoxyribonucleic acid (DNA) damage in targeted cancer cells by interfering with the action of topoisomerase II, a critical enzyme enabling cell proliferation.

Berubicin was developed by Dr. Waldemar Priebe, Professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Center, and demonstrated positive responses that include one durable complete response in Phase 1 human clinical trial conducted previously by Reata Pharmaceuticals, Inc.

Mariusz Olejniczak, CEO of WPD commented, “We are very excited for the ability to share our Phase I pediatric clinical trial protocol with the members of the pediatric oncology society.”

“This will be a great opportunity to promote our project and to establish the possibility for future cooperation,” added Olejniczak.

WPD also announces it has engaged Strikepoint Media LLC., to provide digital marketing and brand awareness support.

WPD has agreed to pay Strikepoint US$50,000 for a 3-month digital media term commencing on April 26, 2021.

Strikepoint will not receive any securities of the Company as compensation for their services.

WPD is a biotechnology research and development company with a focus on oncology and virology, namely research and development of medicinal products involving biological compounds and small molecules.

WPD Pharmaceuticals Inc. (WBIO) is down 1.72 per cent and is trading at C$0.28 at 12:24 pm ET.

More From The Market Herald
WELL Health - Chairman & CEO Hamed Shahbazi

" WELL Health (TSX:WELL) closes $34.5M public offering

WELL Health Technologies Corp. (WELL) has completed a bought deal public offering for proceeds of $34.5 million.

" Simply Better Brands (TSXV:SBBC) enters the weight loss category

Simply Better Brands (SBBC) has launched its entry into the weight loss category with a PureKana Keto Gummy.

" Cardiol Therapeutics (TSX:CRDL) appoints new directors

Cardiol Therapeutics (CRDL) has appointed Teri Loxam and Chris Waddick to its Board of Directors, effective immediately.

" Leveljump Healthcare (TSXV:JUMP) provides Telehospital purchase update

Leveljump Healthcare (JUMP) has provided the following update on its pending acquisition of Telehospital Corp.